Trends in PCSK9 Inhibitor Prescriptions before and after the Price Reduction in Patients with Atherosclerotic Cardiovascular Disease

Background: Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors reduce low-density lipoprotein (LDL) cholesterol and cardiovascular event rates, yet due to their high price remain underutilized and difficult to prescribe in clinical practice. In March 2018, their price was significantly...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Alex, Johnson, Drew, Banks, Joshua, Keith, Scott W., Karalis, Dean G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432238/
https://www.ncbi.nlm.nih.gov/pubmed/34501275
http://dx.doi.org/10.3390/jcm10173828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432238/
https://www.ncbi.nlm.nih.gov/pubmed/34501275
http://dx.doi.org/10.3390/jcm10173828

Ejemplares similares